Blood Pressure Affecting Patents (Class 514/15.6)
-
Patent number: 11666584Abstract: The invention relates to a new method for the prevention and treatment of wave burst arrhythmia by administering a gestagen having an androgenic effect.Type: GrantFiled: April 18, 2017Date of Patent: June 6, 2023Assignees: ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE (INSERM), SORBONNE UNIVERSITÉInventors: Joe-Elie Salem, Christian Funck-Brentano, Anne Bachelot, Xavier Waintraub
-
Patent number: 11414474Abstract: There is provided a novel adrenomedullin derivative capable of sustainably acting for a longer period than natural adrenomedullin. The invention relates to a compound represented by formula (I): A-Ln-B (I), wherein A is a modifying group selected from the group consisting of a palmitoyl group and a polyethylene glycol group, L is a divalent linking group, n is an integer of 0 or 1, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is bound to the modifying group A or the linking group L via the N-terminal amino group of the peptide moiety B, or a salt thereof, or a hydrate thereof.Type: GrantFiled: March 20, 2015Date of Patent: August 16, 2022Assignee: University of MiyazakiInventors: Kazuo Kitamura, Johji Kato, Keishi Kubo, Kenji Kuwasako, Shigeru Kubo, Kumiko Kumagaye
-
Patent number: 11096983Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 6.5 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.Type: GrantFiled: April 12, 2019Date of Patent: August 24, 2021Assignee: The George Washington University a Congressionally Chartered Not-for-Profit CorporationInventor: Lakhmir S. Chawla
-
Patent number: 10960045Abstract: A method of treating epidermolysis bullosa comprising administering to a subject suffering from epidermolysis bullosa an angiotensin (1-7) peptide is described. In some embodiments, methods of treating a complication of epidermolysis bullosa are described including administering to a subject suffering from one or more complications of epidermolysis bullosa an angiotensin (1-7) peptide, wherein the administration results in a reduction in the intensity, severity, duration, or frequency of at least one symptom or feature of the one or more complications of epidermolysis bullosa.Type: GrantFiled: October 14, 2016Date of Patent: March 30, 2021Assignee: Constant Therapeutics LLCInventor: Richard Franklin
-
Patent number: 10856562Abstract: A flavor composition comprising a peptide which comprises pyroglutamic acid or ?-glutamic acid, a second amino acid and optionally a third amino acid. The peptides can be added to a food product to increase saltiness, umami, bitterness, astringency or sourness intensity.Type: GrantFiled: January 22, 2014Date of Patent: December 8, 2020Assignee: MARS, INCORPORATEDInventors: John Didzbalis, John P. Munafo
-
Patent number: 10834946Abstract: A flavor composition containing at least one dipeptide or tripeptide compound that can be used to enhance the taste of edible compositions including sweet goods, such as confectionery goods, and savory goods, such as pet foods.Type: GrantFiled: January 22, 2014Date of Patent: November 17, 2020Assignee: Mars, IncorporatedInventors: John Didzbalis, John P. Munafo
-
Patent number: 10765722Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.Type: GrantFiled: September 19, 2018Date of Patent: September 8, 2020Assignee: The George Washington University a Congressionally Chartered Not-for-Profit CorporationInventor: Lakhmir S. Chawla
-
Patent number: 9403870Abstract: The invention is directed to methods for extracting phosvitin from egg yolk involving contacting the egg yolk or egg yolk protein granules with a solution having a salt concentration of about 10% to form a mixture; optionally, heating the mixture; adjusting the pH of the mixture to separate phosvitin from other proteins; recovering the phosvitin. The phosvitin extract may be dephosphorylated and hydrolyzed to produce phosvitin phosphopeptides.Type: GrantFiled: June 11, 2012Date of Patent: August 2, 2016Assignee: THE GOVERNORS OF THE UNIVERSITY OF ALBERTAInventors: Jianping Wu, Bo Lei, Jiandong Ren
-
Patent number: 9220745Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.Type: GrantFiled: December 18, 2014Date of Patent: December 29, 2015Assignee: The George Washington University, a Congressionally Not-for-Profit CorporationInventor: Lakhmir Chawla
-
Patent number: 9107870Abstract: The present invention provides, among other things, methods of treating Marfan Syndrome and/or a Marfan-related disorder including administering to a subject suffering from or susceptible to Marfan Syndrome and/or a Marfan-related disorder an angiotensin (1-7) peptide. In some embodiments, the angiotensin (1-7) peptide is administered at an effective dose periodically at an administration interval such that at least one symptom or feature of Marfan Syndrome and/or a Marfan-related disorder is reduced in intensity, severity, duration, or frequency or has delayed in onset.Type: GrantFiled: October 3, 2014Date of Patent: August 18, 2015Assignee: Tarix Phamaceuticals Ltd.Inventor: Richard Franklin
-
Publication number: 20150126432Abstract: Compounds of formula (I), salts thereof, and compositions and uses thereof are described. The compounds are useful as V1a vasopressin agonists, for the treatment of e.g., complications of cirrhosis, including bacterial peritonitis, HRS2 and refractory ascites.Type: ApplicationFiled: May 9, 2013Publication date: May 7, 2015Inventors: Kazimierz Wisniewski, Geoffrey S. Harris, Robert Felix Galyean
-
Patent number: 8940685Abstract: The present invention discloses a method for producing antihypertensive active peptides with corn germ protein as the material. The method comprises an alkali-heat treatment and continuous enzymolysis of the corn germ protein. The components with molecular weight less than 1000 Da in the active peptides obtained according to the present method account for more than 92%, and alanine-tyrosine (Ala-Tyr, AY) as the characteristic peptide fragments in the antihypertensive peptides accounts for more than 0.6%, so that the active peptides have a good ACE inhibitory activity in vitro as well as stability against temperature, pH and major gastrointestinal digestive enzymes, and have a significant effect of lowering blood pressure on spontaneous hypertension rats in vivo. The active peptides can be applied as a new functional nutrient to development and production of food, health food and pharmaceutical.Type: GrantFiled: May 14, 2013Date of Patent: January 27, 2015Assignee: China National Research Institute of Food and Fermentation IndustriesInventors: Muyi Cai, Ruizeng Gu, Weixue Yi, Jun Lu, Yong Ma, Zhe Dong, Yaguang Xu, Xingchang Pan, Yongqing Ma, Feng Lin, Zhentao Jin, Liang Chen, Lu Lu, Wenying Liu
-
Patent number: 8921306Abstract: The present invention relates to nociceptin peptide mimetics that have ?-helical structures and bind to and modulate the opioid receptor-like-1 (ORL-1) receptor. The peptide mimetics are constrained cyclic nociceptin analogs which have either agonist or antagonist activity. Pharmaceutical compositions comprising the nociceptin peptide mimetics and methods of treating or preventing a disease or condition ameliorated by modulating the ORL-1 receptor are also described.Type: GrantFiled: June 7, 2011Date of Patent: December 30, 2014Assignee: The University of QueenslandInventors: David Fairlie, Rosemary Sharon Harrison, Nicholas Evan Shepherd
-
Patent number: 8912137Abstract: Methods and materials for diagnosing and treating heart conditions (e.g., heart failure) and kidney conditions (e.g., kidney failure) are described.Type: GrantFiled: September 14, 2012Date of Patent: December 16, 2014Assignee: Mayo Foundation for Medical Education and ResearchInventors: Shuchong Pan, Robert D. Simari
-
Patent number: 8906857Abstract: The ratio of concentrations of pro-adrenomedullin (pro-ADM)/pro-endothelin (pro-END) immunoreactivity in body fluids of critically ill patients is used as for the diagnosis, course control and prognosis, including an assessment of the mortality risk, of severe life threatening diseases. Further, a treatment of critically ill patients having high levels of pro-ADM but insufficient levels of pro-END immunoreactivities with a medicament comprising vasoconstrictive endothelin or its precursors, and/or endothelin agonists or adrenomedullin antagonists is provided.Type: GrantFiled: February 3, 2009Date of Patent: December 9, 2014Assignee: B.R.A.H.M.S. GmbHInventors: Andreas Bergmann, Joachim Struck, Nils G. Morgenthaler
-
Patent number: 8889629Abstract: The invention relates to the use of a cyclic undecapeptide, with the structure in formula (I), for the preparation of a medicament for administration during a myocardial ischaemic event.Type: GrantFiled: January 10, 2006Date of Patent: November 18, 2014Assignee: Debiopharm International SAInventors: Pietro Scalfaro, Jean-Maurice Dumont, Grégoire Vuagniaux
-
Patent number: 8883731Abstract: An agent for reducing risk in onset of diseases ascribable to non-dipping circadian profile of blood pressure is provided. This agent is capable of effectively lowering SBP from night to early morning in individuals with non-dipping circadian profile of blood pressure, in particular, normal individuals with normal SBP and DBP among them, and is thus capable of reducing risk in onset, particularly likely in the morning, of diseases caused by circadian variation of blood pressure. The agent is intended for administration to such subjects, and contains a hydrolysate or a concentrate thereof, containing Val-Pro-Pro and Ile-Pro-Pro and obtained by hydrolysis of animal milk protein.Type: GrantFiled: March 26, 2013Date of Patent: November 11, 2014Assignee: CALPIS Co., LtdInventors: Mari Takahashi, Naoyuki Yamamoto, Kazuhisa Yamada, Toshirou Iketani
-
Patent number: 8883965Abstract: The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification.Type: GrantFiled: February 5, 2007Date of Patent: November 11, 2014Assignee: Ferring B.V.Inventors: Kazimierz Wisniewski, Robert Felix Galyean
-
Publication number: 20140315818Abstract: The invention relates to methods for altering biological parameters in a subject, such as reducing blood pressure in a subject, by displacing CLIP, using a CLIP inhibitor. The methods are useful for treating disorders such as preeclampsia and high blood pressure.Type: ApplicationFiled: November 30, 2012Publication date: October 23, 2014Inventors: Martha Karen Newell, Brett Mitchell, Evan Newell
-
Patent number: 8828386Abstract: A method lessening intraventricular hemorrhage in the fetus of a gravid human patient is provided where the patient is administered a therapeutically effective amount of digoxin antibody.Type: GrantFiled: February 13, 2012Date of Patent: September 9, 2014Assignees: Glenveigh Pharmaceuticals, LLC, CDA Royalty Investors, LLCInventor: Charles David Adair
-
Patent number: 8785386Abstract: The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) wherein R1 represents a —CO—(CH2)n—COR2 group (wherein n is an integer of 1 to 4, and R2 is (2-1) a hydroxy group; (2-2) a lower alkoxy group optionally substituted with a hydroxy group, a lower alkanoyl group, a lower alkanoyloxy group, a lower alkoxycarbonyloxy group, a cycloalkyloxycarbonyloxy group, or 5-methyl-2-oxo-1,3-dioxol-4-yl; or (2-3) an amino group optionally substituted with a hydroxy-lower alkyl group), or the like.Type: GrantFiled: September 24, 2013Date of Patent: July 22, 2014Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Kazumi Kondo, Yasuhiro Menjo, Takahiro Tomoyasu, Shin Miyamura, Yuso Tomohira, Takakuni Matsuda, Keigo Yamada, Yusuke Kato
-
Patent number: 8778881Abstract: The present application relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification.Type: GrantFiled: March 1, 2012Date of Patent: July 15, 2014Assignee: Ferring B.V.Inventors: Kazimierz Wisniewski, Claudio Schteingart, Regent LaPorte, Robert Felix Galyean, Pierre J.M. Riviere
-
Publication number: 20140193393Abstract: Methods of using an ETB receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.Type: ApplicationFiled: January 7, 2014Publication date: July 10, 2014Applicant: MIDWESTERN UNIVERSITYInventor: ANIL GULATI
-
Publication number: 20140194358Abstract: Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration.Type: ApplicationFiled: October 28, 2013Publication date: July 10, 2014Applicant: Children's Medical Center CorporationInventors: Avner Adini, Robert D'Amato
-
Publication number: 20140155329Abstract: Long-acting agonistic analogs for CLR/RAMP receptors are provided that have an extended half-live in vivo.Type: ApplicationFiled: April 5, 2012Publication date: June 5, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Sheau Yu Hsu, Chia Lin Chang
-
Publication number: 20140094409Abstract: Brain prorenin and the (pro)renin receptor (PRR) have a functional role in the development of hypertension. The present disclosure presents functional PRR antagonistic peptides (e.g., PR10, PR20, PR30, and PR40). In addition, modified peptides comprising one or more thioether-bridges that are stable and strong PRR antagonists are also provided. Methods for treating and preventing hypertension, including neurogenic hypertension, and diabetes with a PRR antagonist are also provided.Type: ApplicationFiled: September 19, 2013Publication date: April 3, 2014Inventor: Yumei FENG
-
Publication number: 20140073562Abstract: A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders.Type: ApplicationFiled: March 15, 2012Publication date: March 13, 2014Applicant: OPTINOSE ASInventor: Per Gisle Djupesland
-
Patent number: 8669229Abstract: The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) wherein R1 represents a —CO—(CH2)n—COR2 group (wherein n is an integer of 1 to 4, and R2 is (2-1) a hydroxy group; (2-2) a lower alkoxy group optionally substituted with a hydroxy group, a lower alkanoyl group, a lower alkanoyloxy group, a lower alkoxycarbonyloxy group, a cycloalkyloxycarbonyloxy group, or 5-methyl-2-oxo-1,3-dioxo-4-yl; or (2-3) an amino group optionally substituted with a hydroxy-lower alkyl group), or the like.Type: GrantFiled: June 26, 2008Date of Patent: March 11, 2014Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Kazumi Kondo, Yasuhiro Menjo, Takahiro Tomoyasu, Shin Miyamura, Yuso Tomohira, Takakuni Matsuda, Keigo Yamada, Yusuke Kato
-
Patent number: 8563512Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: GrantFiled: December 14, 2011Date of Patent: October 22, 2013Assignee: Theravance, Inc.Inventors: Cameron Smith, Melissa Fleury, Roland Gendron, Ryan Hudson, Adam D. Hughes
-
Patent number: 8551938Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: GrantFiled: September 23, 2010Date of Patent: October 8, 2013Assignee: Alcon Research, Ltd.Inventors: Mark R. Hellberg, Iok-Hou Pang
-
Patent number: 8546523Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: GrantFiled: September 23, 2010Date of Patent: October 1, 2013Assignee: Alcon Research, Ltd.Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Uwe Richter, Bernadett Simon, Edgar Specker, Markus Woischnik, Mark R. Hellberg
-
Patent number: 8546322Abstract: The present invention provides compositions comprising amiloride amino acid and peptide conjugates. Efficient methods are also provided for administering the compositions for treating cancer and for delivering an amiloride conjugate into cancer cells in a subject in need thereof.Type: GrantFiled: August 1, 2008Date of Patent: October 1, 2013Assignee: The Regents of the University of CaliforniaInventors: Fredric A. Gorin, Michael H. Nantz
-
Patent number: 8536135Abstract: The present invention is related to methods of generating adaptive biochemical signatures in live cells and the use of said signatures to identify diagnostic and therapeutic modalities for human disease. The methods described herein comprise contacting a provocative agent to live cells and measuring and analyzing adaptive readouts. The methods of the invention may be used for therapeutic or diagnostic purposes.Type: GrantFiled: February 25, 2011Date of Patent: September 17, 2013Assignee: Ontherix, Inc.Inventor: Desmond Mascarenhas
-
Publication number: 20130210732Abstract: An agent for reducing risk in onset of diseases ascribable to non-dipping circadian profile of blood pressure is provided. This agent is capable of effectively lowering SBP from night to early morning in individuals with non-dipping circadian profile of blood pressure, in particular, normal individuals with normal SBP and DBP among them, and is thus capable of reducing risk in onset, particularly likely in the morning, of diseases caused by circadian variation of blood pressure. The agent is intended for administration to such subjects, and contains a hydrolysate or a concentrate thereof, containing Val-Pro-Pro and Ile-Pro-Pro and obtained by hydrolysis of animal milk protein.Type: ApplicationFiled: March 26, 2013Publication date: August 15, 2013Applicant: CALPIS CO., LTD.Inventor: Calpis Co., Ltd.
-
Patent number: 8486885Abstract: This application describes a family of compounds acting as ?-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.Type: GrantFiled: December 28, 2009Date of Patent: July 16, 2013Assignee: Trevena, Inc.Inventors: Dennis Yamashita, Xiao-Tao Chen
-
Publication number: 20130157928Abstract: The present invention relates to nociceptin peptide mimetics that have ?-helical structures and bind to and modulate the opioid receptor-like-1 (ORL-1) receptor. The peptide mimetics are constrained cyclic nociceptin analogues which have either agonist or antagonist activity. Pharmaceutical compositions comprising the nociceptin peptide mimetics and methods of treating or preventing a disease or condition ameliorated by modulating the ORL-1 receptor are also described.Type: ApplicationFiled: June 7, 2011Publication date: June 20, 2013Inventors: David Fairlie, Rosemary Sharon Harrison, Nicholas Evan Shepherd
-
Patent number: 8440619Abstract: The object is to provide a novel application of D-allose (e.g., use for prevention of hypertension or hypercardia). Thus, disclosed is a composition for preventing the increase in blood pressure which comprises D-allose as an active ingredient; or a composition containing D-allose and/or a derivative thereof, preferably in an amount of 0.1 to 50% by weight. Preferably, the composition is in a form selected from the group consisting of a food additive, a food material, a beverage/food, a health beverage/food, a pharmaceutical and a feeding stuff which can be used for the prevention and treatment of a cardiovascular system disorder (e.g., hypertension, hypercardia). The increase in blood pressure may be caused by salt-sensitive hypertension. Also disclosed is use of D-allose for preventing the increase in blood pressure (excluding medical practices).Type: GrantFiled: August 31, 2006Date of Patent: May 14, 2013Assignees: National University Corporation Kagawa University, Matsutani Chemical Industry Co., Ltd.Inventors: Masaaki Tokuda, Shoji Kimura, Ken Izumori
-
Publication number: 20130116183Abstract: Described herein are methods of identifying and releasing bioactive peptides from ovotransferrin The method involves (a) contacting ovotransferrin with a reducing agent, a sonication step, a high pressure processing step, a heating step, a fermentation step, or any combination thereof, and (b) contacting the ovotransferrin after step (a) with a hydrolytic enzyme to produce bioactive peptides that exhibit angiotensin converting enzyme inhibitory activity or antioxidant activity when compared to the parent protein. The bioactive peptides may be added to foodstuffs, a medication, or to any potable, ingestible, or edible compositions.Type: ApplicationFiled: March 19, 2010Publication date: May 9, 2013Inventors: Jianping Wu, Kaustav Majumder
-
Publication number: 20130052280Abstract: The use of theobromine for lowering central blood pressure and/or lowering central pulse pressure in humans and derived benefits, and compositions comprising theobromine.Type: ApplicationFiled: January 18, 2011Publication date: February 28, 2013Inventors: Richard Draijer, Bas Van Den Bogaard
-
Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same
Patent number: 8354502Abstract: The invention relates to the production of bioactive products that are derived from milk proteins for the production of bioactive milk products derived from milk proteins, particularly caseins. The 16 inventive peptides can be obtained chemically, biotechnologically or by means of enzymatic treatment from proteins containing same and give rise to peptides with an antimicrobial activity, an in vitro angiotensin converter inhibitor activity and/or antihypertensive activity and/or antioxidant activity. Said nutraceutical products are suitable for use in the food and pharmaceutical industries, both in the form of a hydrolyzate or bioactive peptides.Type: GrantFiled: June 8, 2006Date of Patent: January 15, 2013Assignee: Consejo Superior de Investigaciones CientificasInventors: Isidra Recio Sanchez, Ana Quiros Del Bosque, Blanca Hernandez Ledesma, JoséAngel Gomez Ruiz, Marta Miguel Castro, Maria Lourdes Amigo Garrido, Ivan Lopez Exposito, Maria Mercedes Ramos Gonzalez, Amaya Aleixandre De Artiñano, Mar Contreras Gómez -
Patent number: 8349801Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating myocardial and ischemic disorders associated with G-protein coupled receptor activation.Type: GrantFiled: September 18, 2007Date of Patent: January 8, 2013Assignee: Compugen Ltd.Inventors: Yossi Cohen, Ronen Shemesh, Amir Toporik, Zurit Levine, Assaf Wool, Dvir Dahary, Iris Hecht, Merav Beiman, Galit Rotman, Michal Ayalon-Soffer
-
Patent number: 8329641Abstract: An effective agent for treating ischemic disease, the agent containing human granulocyte colony-stimulating factor (human G-CSF) as an active ingredient is disclosed. By administering this therapeutic agent, an effective therapy particularly for obstructive arteriosclerosis is provided which can eliminate drawbacks with conventional therapies, such as kinesitherapy, pharmacotherapy, and revascularization, and recently proposed therapies, such as gene therapy and intramuscular transplantation of bone marrow cells. Furthermore, the therapeutic agent can be used as an agent for treating ischemic disease, such as ischemic cerebrovascular disorder or ischemic heart disease.Type: GrantFiled: September 13, 2001Date of Patent: December 11, 2012Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tatsuya Miyai, Masahiko Tamura
-
Patent number: 8318673Abstract: An anti-hemorrhage medication pack for administering an anti-hemorrhage drug, in particular for the treatment of hemorrhage caused by trauma in emergency situations comprises an active ingredient selected from the group comprising the 1-24 amino acid sequence of the adrenocorticotropic hormone (ACTH 1-24) and all its fragments and analogues, and analogues of fragments, with agonist activity on the MC4 melanocortin receptors, and all the synthesis agonists, including those with a nonpeptidic structure, of the MC4 melanocortin receptors. An auto-injector (1; 11) includes the drug for automatically injecting a patient with the drug.Type: GrantFiled: July 6, 2007Date of Patent: November 27, 2012Assignee: Health Ricerca e Sviluppo S.R.L.Inventors: Giorgio Noera, Alfio Bertolini
-
Publication number: 20120295851Abstract: Described is an N-terminal hexapeptide fragment of maximakinin, QUB 698.8, which exhibits potent tissue selective actions on smooth muscle. It demonstrates a high degree of selectivity for arterial smooth muscle over small intestinal smooth muscle, causing potent relaxation of arterial smooth muscle, while causing less potent contraction of ileal smooth muscle. It may be used treatment of diseases of the cardiovascular system and in promotion of angiogenesis.Type: ApplicationFiled: June 22, 2012Publication date: November 22, 2012Applicant: The Queen's University of BelfastInventors: Christopher Shaw, Tianbao Chen, Martin O'Rourke, Brian Walker, David Hirst
-
Publication number: 20120282243Abstract: The present invention provides soy sauce that comprises significant amounts of peptides, and, in particular, hypotensive peptide Gly-Tyr and hypotensive peptide Ser-Tyr, exhibiting a high degree of angiotensin-I-converting enzyme-inhibitory activity and has hypotensive effects while containing no hypotensive agent. Target soy sauce is obtained by mixing soy sauce koji having protease activity of 20 to 300 U/g koji with an aqueous common salt solution and subjecting the mixture to heated digestion, followed by compression filtration. Target soy sauce with a good flavor is obtained by adding soy sauce lactic acid bacteria and soy sauce yeast cells to the moromi mash after heated digestion, and subjecting the resultant to fermentation and maturation, followed by compression filtration.Type: ApplicationFiled: December 24, 2010Publication date: November 8, 2012Applicant: KIKKOMAN CORPORATIONInventors: Yoshikazu Endo, Shigeki Tanizawa, Takeharu Nakahara, Hitomi Aota, Hiroki Ono, Yoichi Hanada, Riichiro Uchida
-
Publication number: 20120270771Abstract: The present invention relates to apolipoprotein A-1 mimic peptides, and therapeutic agent for treating hyperlipidemia and diseases related to hyperlipidemia comprising the same. More specifically, the apolipoprotein A-1 mimic peptides of the present invention were manufactured by modifying hydrophilic or hydrophobic face of existing 4F amphipathic peptides to produce Apo A-I mimic peptides which specifically bind with cholesterol ester to allow high density lipoprotein content to increase, and the peptide of which phenylalanine in hydrophobic face of 4F is substituted with 2-naphthylalanine has superior cholesterol efflux capability and cognitive function for lipids to the existing 4F peptides, among the mimic peptides. Thus, the Apo A-I mimic peptides of the present invention can be used as Apo A-I mimic peptides and as a therapeutic agent for treating hyperlipidemia and diseases related to hyperlipidemia.Type: ApplicationFiled: September 30, 2009Publication date: October 25, 2012Applicant: SNU R&DB FOUNDATIONInventor: Jaehoon Yu
-
Publication number: 20120251629Abstract: The present invention relates to a method of treating a patient for a condition where blood flow to a tissue or organ is interrupted. This method involves administering to a patient with a hypoxic condition where blood flow to a tissue or organ is interrupted, or at risk thereof, a compound that reduces the rate of HIF-1? inactivation in cells affected by the condition, thereby treating the patient for the condition. Also disclosed is a method of treating a tumor in a patient. In addition, the present invention relates to methods of identifying compounds as candidate drugs for treatment of hypoxic conditions and for treating tumors in a subject.Type: ApplicationFiled: October 8, 2010Publication date: October 4, 2012Applicant: UNIVERSITY OF ROCHESTERInventor: Marc Halterman
-
Patent number: 8278275Abstract: The present invention relates to methods for enhancing the hemodynamic stability of an individual undergoing surgery by administering a composition comprising a hemoglobin-based oxygen carrier. In one embodiment, the present invention relates to the use of polyalkylene oxide modified hemoglobins with reduced cooperativity and a high oxygen affinity to enhance oxygen offloading as a preventative measure to avoid hemodynamic stability-related complications during surgery.Type: GrantFiled: November 23, 2009Date of Patent: October 2, 2012Assignee: Sangart, Inc.Inventors: Robert M. Winslow, Kim D. Vandegriff
-
Publication number: 20120196808Abstract: The present application relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification.Type: ApplicationFiled: March 1, 2012Publication date: August 2, 2012Applicant: FERRING B.V.Inventors: Kazimierz Wisniewski, Claudio Schteingart, Regent LaPorte, Robert Felix Galyean, Pierre Riviere
-
Publication number: 20120115786Abstract: An agent for reducing risk in onset of diseases ascribable to non-dipping circadian profile of blood pressure is provided. This agent is capable of effectively lowering SBP from night to early morning in individuals with non-dipping circadian profile of blood pressure, in particular, normal individuals with normal SBP and DBP among them, and is thus capable of reducing risk in onset, particularly likely in the morning, of diseases caused by circadian variation of blood pressure. The agent is intended for administration to such subjects, and contains a hydrolysate or a concentrate thereof, containing Val-Pro-Pro and Ile-Pro-Pro and obtained by hydrolysis of animal milk protein. Reduction of risk may be expected in onset, particularly likely in the morning, of various diseases caused by risk of circadian variation of blood pressure, such as cerebral infarction, myocardial infarction,myocardialischemia, atherosclerosis, cardiac failure, cerebral stroke, coronary artery diseases, and peripheral vascular diseases.Type: ApplicationFiled: November 9, 2011Publication date: May 10, 2012Applicant: CALPIS CO., LTD.Inventors: Mari TAKAHASHI, Naoyuki Yamamoto, Kazuhisa Yamada, Toshirou Iketani